Dr Reddy’s laboratories to market ‘DiaResQ’
Under the new licensing agreement signed Dr Reddy’s Laboratories will now get the rights to market and distribute nutritional products including ‘DiaResQ’ PanTheryx, Inc, a US-based global medical nutrition company, and pharma major Dr.Reddy's Laboratories Ltd., have entered into a marketing and distribution agreement for a multi-country supply and licensing contract.Under the...
Login or Register to read the full article
Under the new licensing agreement signed Dr Reddy’s Laboratories will now get the rights to market and distribute nutritional products including ‘DiaResQ’
PanTheryx, Inc, a US-based global medical nutrition company, and pharma major Dr.Reddy's Laboratories Ltd., have entered into a marketing and distribution agreement for a multi-country supply and licensing contract.
Under the new development, Dr Reddy’s laboratories have bagged the exclusive rights for the breakthrough nutritional intervention 'DiaResQ' for infectious diarrhea in India and Nepal. Dr. Reddy's laboratories will market the product in India and Nepal under the Reliqua brand, as confirmed by IANS.
"This partnership further validates DiaResQ's potential to improve the well-being and quality of life of millions of children and their families globally," said PanTheryx president and CEO Mark A. Braman.
"Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it," said Dr. Reddy's co-chairman and CEO, G.V. Prasad.
Since Dr Reddy’s will be a multi-country supply partner for PanTheryx nutritional products, the decision to market DiaResQ' is under due consideration and process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select Latin American markets.
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
Millions of Indians who suffer from the infectious disease are likely to benefit from this partnership. The diarrhea health challenge is most prevalent in children under the age of 5 with almost 760,000 deaths (in the under 5 age bracket) reported every year. It is a global health challenge in context of Pediatric infectious killing nearly as many children as HIV/AIDS, malaria and measles combined.
PanTheryx, Inc, a US-based global medical nutrition company, and pharma major Dr.Reddy's Laboratories Ltd., have entered into a marketing and distribution agreement for a multi-country supply and licensing contract.
Under the new development, Dr Reddy’s laboratories have bagged the exclusive rights for the breakthrough nutritional intervention 'DiaResQ' for infectious diarrhea in India and Nepal. Dr. Reddy's laboratories will market the product in India and Nepal under the Reliqua brand, as confirmed by IANS.
"This partnership further validates DiaResQ's potential to improve the well-being and quality of life of millions of children and their families globally," said PanTheryx president and CEO Mark A. Braman.
"Our agreement with PanTheryx is another step towards ensuring good health can be delivered to those who need it," said Dr. Reddy's co-chairman and CEO, G.V. Prasad.
Since Dr Reddy’s will be a multi-country supply partner for PanTheryx nutritional products, the decision to market DiaResQ' is under due consideration and process for Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select Latin American markets.
DiaResQ helps promote intestinal repair and boost natural immune defenses, resulting in the restoration of normal digestive function. The product was recently recognized in Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030.
Millions of Indians who suffer from the infectious disease are likely to benefit from this partnership. The diarrhea health challenge is most prevalent in children under the age of 5 with almost 760,000 deaths (in the under 5 age bracket) reported every year. It is a global health challenge in context of Pediatric infectious killing nearly as many children as HIV/AIDS, malaria and measles combined.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd